Immunovant, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Immunovant is a clinical-stage biopharmaceutical company developing monoclonal antibodies that target the neonatal Fc receptor (FcRn) to treat autoimmune diseases. Its lead candidate, batoclimab, and follow-on antibody IMVT-1402 are being studied in conditions such as myasthenia gravis, thyroid eye disease, and other immune-mediated disorders.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Stout Jay SChief Technology Officer | Sell | $75K | 2,595at $28.94 | Oct 21, 2026 |
| Stout Jay SChief Technology Officer | Sell | $71K | 2,213at $32.06 | Oct 7, 2026 |
| Stout Jay SChief Technology Officer | Sell | $51K | 1,596at $32.06 | Oct 7, 2026 |
| Gloria MelanieChief Operating Officer | Sell | $72K | 2,241at $32.06 | Oct 7, 2026 |
| Van Tuyl ChristopherChief Legal Officer | Sell | $43K | 1,327at $32.06 | Oct 7, 2026 |
| Venker EricChief Executive Officer | Sell | $120K | 3,506at $34.11 | Oct 2, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable IMVT activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.